Pathological examination of a surgical specimen confirmed necrotic bone.
Osteonecrosis of the jaw has been described in association with bisphosphonate therapy or herpes zoster and is seen especially in patients undergoing cancer therapy.
Osteonecrosis of the jaw Osteonecrosis of the jaw (ONJ, avascular necrosis of the jaw), often associated with pain, swelling, exposed bone, local infection, and pathologic fracture of the jaw, has been described in patients receiving chronic bisphosphonate therapy.
Risk factors for developing ONJ include intravenous bisphosphonates, cancer and anti-cancer therapy, duration of exposure, dental extractions, dental implants, poorly fitting dentures, glucocorticoids, smoking, preexisting dental disease
However, if a patient has been treated for more than three years, they recommend discontinuing oral bisphosphonates for three months prior to performing the dental surgery and restarting when the bone has healed
Bisphosphonate use in malignant disease Use of bisphosphonates in patients with malignant diseases such as multiple myeloma and metastatic breast cancer has been suggested as a risk factor for development of osteonecrosis of the jaw.
Treatment with a combination of antimicrobial agents and surgical débridement was eventually successful.
TREATMENT The treatment of osteonecrosis remains one of the most controversial subjects in the orthopedic literature. The goal of therapy is to preserve the native joint for as long as possible. There are three main therapeutic options: Conservative management Joint preserving procedures Joint replacement